Aaron Hoffman, PhD
Department of Epidemiology
Tulane University School of Public Health and Tropical Medicine
Tulane Cancer Center
1430 Tulane Avenue, SL-68
New Orleans, LA 70112
Phone: (504) 988-1560
Molecular and Environmental Epidemiology of Cancer; Circadian Genetics and the Role of Circadian Genes in Carcinogenic Processes; Small RNAs in Cancer; Environmental Factors in Gene Regulation
- PhD, Yale University School of Public Health, New Haven, CT
- BS, Iowa State University, Ames, IA
- Competitive Travel Grant, Yale University Graduate School (2009)
- Epidemiology Departmental Travel Award, Yale School of Public Health (2009)
- Member, American Association for Cancer Research/Molecular Epidemiology Working Group
- Member, The American Society of Human Genetics
- Member, New York Academy of Sciences
Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, et al. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways. BMC Cancer. 2010;10:110. PMCID: 2860360.
Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, et al. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer Prev Res (Phila). 2010;3(4):539-48.
Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, et al. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010;70(4):1459-68.
Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat. 2010.
Leaderer D, Hoffman AE, Zheng T, Weidhaas J, Paranjape T, Paulson J, Zhu Y. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2010;2(1):9-18
Yi C, Mu L, de la Longrais IA, Sochirca O, Arisio R, Yu H, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat. 2010;120(3):663-9.
Kim, SJ, Hoffman A, Fu A, Zheng T, Zhu Y. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer. Cancer Letters (In Press)
Zhu Y, Stevens RG, Hoffman AE, FitzGerald L, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69(24):9315-22
Hoffman AE, Zheng T, Yi C, Weidhaas J, Slack F, Zhang Y, Paranjape T, Leaderer D, Zhu Y (2009) miR-196a-2 in breast tumorigenesis: evidence from a genetic and epigenetic association study and functional analysis. Cancer Res 69(14):5970-7
Hoffman AE , Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford T, Zhu Y (2009) Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene Cryptochrome 2. Cancer Res 69(8):3605-13
Yi C, Zheng T, Leaderer D, Hoffman A, Zhu Y (2009) Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett. 284(2):149-56
Yi C, Mu L, Rigault de la Longrais IA, Sochirca O, Arisio R, Yu H, Hoffman AE, Zhu Y, Katsaro D (2009) The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 120(3):663-9
Hoffman AE, Zheng T, Ba Y, Zhu Y (2008) The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6:1461-1468
Zhu Y, Hoffman A, Wu X, Zhang H, Zhang Y, Leaderer D, Zheng T (2008) Correlating observed odds ratios from lung cancer case-control studies to SNP functional scores predicted by bioinformatic tools. Mutat Res 639:80-88
Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, Brown HN, Zheng T (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 107:421-425
Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X, Zheng T (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 120:432-435
My research focuses on the molecular epidemiology of cancer, with a particular interest in the influence of genetic and epigenetic mechanisms of circadian disruption on cancer susceptibility. I am also interested in more broad analyses of the inter-individual variability in gene expression, and the extent to which epigenetic mechanisms such as post-transcriptional gene regulation by small non-coding RNA species and other non-traditional regulatory instruments (e.g. alternative polyadenylation), influence cancer-relevant processes and contribute to the complex risk structure which is observable at the population level. In each case, the goal of my research is to generate insights with translational implications which may be useful for the treatment and prevention of cancer.
Level of Instruction:
[ View all Epidemiology Faculty ]